A phase 2, open-label, multicenter study of INCAGN01876 (anti-GITR agonist) in combination with retifanlimab (anti–PD-1) in recurrent or metastatic head and neck squamous cell carcinoma

Authors

Rom Leidner, ProvidenceFollow
Robert Haddad
Nawel Bourayou
Sonia Ioannidis
Feng Zhou
Zhiwan Dong
Ezra Cohen

Document Type

Presentation

Publication Date

11-8-2022

Keywords

oregon; portland; chiles

Clinical Institute

Cancer

Department

Oncology

Comments

SITC Annual Meeting; November 8-12; Boston, MA. 2022: 677

Recommended Citation

Leidner, Rom; Haddad, Robert; Bourayou, Nawel; Ioannidis, Sonia; Zhou, Feng; Dong, Zhiwan; and Cohen, Ezra, "A phase 2, open-label, multicenter study of INCAGN01876 (anti-GITR agonist) in combination with retifanlimab (anti–PD-1) in recurrent or metastatic head and neck squamous cell carcinoma" (2022). Articles, Abstracts, and Reports. 6982.
https://digitalcommons.providence.org/publications/6982